La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Replimune Group a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Replimune Group..

Replimune Group (NASDAQ:REPL) Azioni, Catena delle Opzioni

REPLIMUNE GROUP INC

Replimune Group

Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

WIIM

Wallbox shares are trading lower after the company announced a 20-for-1 reverse stock split.

News

Management

NUWE

Nuwellis Names John Erb CEO, Effective June 27, 2025

UBS analyst A.J. Rice downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Buy to Neutral and lowers the price target from $80 to $45.

Downgrades

Price Target

Analyst Ratings

UBS Downgrades Centene to Neutral, Lowers Price Target to $45

FLYE

Fly-E Group shares are trading lower after the company announced a 1-for-5 reverse stock split.

Instil Bio shares are trading higher after the company announced it received FDA Clearance for IND of AXN-2510.

Macro Economic Events

Econ #s

Economics

USA ADP Nonfarm Employment Change (Jun) -33K Vs 99K Est

JP Morgan analyst John Stansel downgrades Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from Overweight to Neutral and lowers the price target from $75 to $48.

JP Morgan Downgrades Centene to Neutral, Lowers Price Target to $48

Cyngn shares are trading higher after the company announced that it has secured $32 million in funding.

JP Morgan analyst Froylan Mendez downgrades Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) from Overweight to Neutral and lowers the price target from $10.5 to $8.8.

ARCO

JP Morgan Downgrades Arcos Dorados Holdings to Neutral, Lowers Price Target to $8.8

Bon Natural Life shares are trading higher after the company announced a sales distribution agreement with Huahai Keyuan.

BMRA

Biomerica shares are trading higher after the American Medical Association issued a CPT code in the Proprietary Laboratory Analysis category for the company's inFoods test.

<ul>
<li>PLA Code issuance by the American Medical Association CPT editorial panel marks a meaningful step toward attaining health insurance reimbursement and expanded patient access for inFoods&#xAE; IBS &nbsp;</li>
<li>inFoods&#xAE; IBS provides personalized identification of food triggers to substantially improve IBS-related symptoms like bloating, abdominal pain, diarrhea, and constipation &nbsp;</li>
</ul>
IRVINE, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRA#NASDAQ">BMRA</a>), a global biomedical company focused on innovative gastroenterology diagnostics, today announced that the American Medical Association CPT editorial panel has issued a Current Procedural Terminology (CPT&#xAE;) code in the Proprietary Laboratory Analysis (PLA) code category for the Company's inFoods&#xAE; IBS test.
This newly granted PLA code assigns a unique identifier to the test, allowing for the submission of claims to Medicare and private insurers for the Company's inFoods IBS test once the code becomes effective on October 1, 2025. The PLA code represents a next step on the pathway to expand patient access to the inFoods&#xAE; IBS test.
Milestone to Expand Patient Access
The issuance of a PLA code represents a milestone in Biomerica's commercialization strategy and its efforts to expand access to inFoods&#xAE; IBS. A test specific billing code allows for transparency in claims submission and adjudication for inFoods&#xAE; IBS.

Biotech

General

Biomerica's inFoods IBS Test Receives AMA PLA Code, Advancing Path To Insurance Reimbursement And Wider Patient Access

MOGO

Mogo shares are trading higher after the company announced a $50 million bitcoin treasury authorization.

<h3>Gainers</h3>
<ul>
<li>Perfect Moment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PMNT#AMEX">PMNT</a>) shares rose 22.2% to $0.28 during Wednesday's pre-market session. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Naas Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) stock moved upwards by 12.42% to $0.9. The market value of their outstanding shares is at $11.0 million. </li>
<li>Ballys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) stock increased by 8.01% to $12.0. The market value of their outstanding shares is at $544.5 million. </li>
<li>Massimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAMO#NASDAQ">MAMO</a>) shares moved upwards by 5.95% to $2.85. The market value of their outstanding shares is at $111.7 million. </li>
<li>JX Luxventure Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JXG#NASDAQ">JXG</a>) shares moved upwards by 5.62% to $1.69. The company's market cap stands at $6.4 million. </li>
<li>Kaixin Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KXIN#NASDAQ">KXIN</a>) stock rose 5.49% to $0.95. The company's market cap stands at $1.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Dogness (Intl) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOGZ#NASDAQ">DOGZ</a>) shares fell 24.9% to $9.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $181.4 million. </li>
<li>Fly-E Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLYE#NASDAQ">FLYE</a>) shares fell 13.39% to $0.85. The company's market cap stands at $52.1 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares fell 12.88% to $0.14. The company's market cap stands at $8.3 million. </li>
<li>Playboy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) stock decreased by 5.57% to $1.51. The company's market cap stands at $150.3 million. </li>
<li>Lead Real Estate Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRE#NASDAQ">LRE</a>) stock fell 5.56% to $1.7. The market value of their outstanding shares is at $24.5 million. </li>
<li>ECD Automotive Design (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECDA#NASDAQ">ECDA</a>) stock decreased by 5.0% to $0.25. The company's market cap stands at $10.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BALY

DOGZ

ECDA

KXIN

MAMO

NAAS

PLBY

PMNT

12 Consumer Discretionary Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock rose 24.9% to $3.11 during Wednesday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares rose 12.58% to $24.69. The company's market cap stands at $143.8 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares increased by 11.72% to $1.62. The company's market cap stands at $6.6 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares increased by 11.57% to $1.35. The market value of their outstanding shares is at $3.8 million. </li>
<li>Modular Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODD#NASDAQ">MODD</a>) shares rose 11.53% to $0.79. The market value of their outstanding shares is at $38.4 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares rose 11.11% to $1.1. The company's market cap stands at $4.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) shares fell 30.2% to $39.57 during Wednesday's pre-market session. The market value of their outstanding shares is at $28.1 billion. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares declined by 27.32% to $1.49. The company's market cap stands at $8.9 million. </li>
<li>Genenta Science (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNTA#NASDAQ">GNTA</a>) stock decreased by 12.31% to $3.35. The market value of their outstanding shares is at $69.8 million. </li>
<li>Vaxart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VXRT#NASDAQ">VXRT</a>) stock declined by 10.86% to $0.41. The market value of their outstanding shares is at $104.9 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares fell 10.71% to $0.73. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) shares decreased by 9.93% to $1.27. The company's market cap stands at $4.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GNTA

MBIO

MODD

NIVF

REVB

SBFM

SCNI

SNGX

SONN

VXRT

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Earlyworks Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELWS#NASDAQ">ELWS</a>) shares moved upwards by 80.0% to $3.42 during Wednesday's pre-market session. The company's market cap stands at $5.7 million. </li>
<li>Globavend Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) stock rose 25.52% to $0.08. The market value of their outstanding shares is at $1.0 million. </li>
<li>Cycurion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCU#NASDAQ">CYCU</a>) shares moved upwards by 15.5% to $0.42. The market value of their outstanding shares is at $11.3 million. </li>
<li>Royalty Management Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMCO#NASDAQ">RMCO</a>) stock increased by 13.84% to $1.48. The market value of their outstanding shares is at $19.4 million. </li>
<li>Greenbrier Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBX#NYSE">GBX</a>) stock moved upwards by 13.82% to $53.5. The company's market cap stands at $1.4 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>374Water (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCWO#NASDAQ">SCWO</a>) stock increased by 10.44% to $0.25. The company's market cap stands at $32.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) stock decreased by 46.1% to $6.0 during Wednesday's pre-market session. The market value of their outstanding shares is at $20.0 million. </li>
<li>Pinnacle Food Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PFAI#NASDAQ">PFAI</a>) stock declined by 20.51% to $1.93. The company's market cap stands at $28.4 million. </li>
<li>Polar Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POLA#NASDAQ">POLA</a>) shares declined by 9.24% to $1.77. The company's market cap stands at $4.8 million. </li>
<li>BrightView Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) stock declined by 8.79% to $15.37. The company's market cap stands at $1.6 billion. </li>
<li>Webus International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WETO#NASDAQ">WETO</a>) stock fell 8.3% to $1.88. The company's market cap stands at $45.1 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) shares decreased by 6.49% to $1.01. The market value of their outstanding shares is at $120.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BGLC

CYCU

ELWS

LGCL

PFAI

POLA

RMCO

SCWO

WETO

12 Industrials Stocks Moving In Wednesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) stock increased by 45.4% to $1.31 during Wednesday's pre-market session. The company's market cap stands at $65.4 million. </li>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares moved upwards by 15.87% to $14.83. The company's market cap stands at $22.4 million. </li>
<li>Intchains Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICG#NASDAQ">ICG</a>) stock moved upwards by 14.03% to $2.25. The company's market cap stands at $119.1 million. </li>
<li>BitMine Immersion Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) stock rose 12.63% to $51.81. The company's market cap stands at $278.9 million. </li>
<li>Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) stock rose 9.95% to $20.44. The market value of their outstanding shares is at $1.1 billion. </li>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) stock increased by 8.91% to $0.17. The company's market cap stands at $9.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Argo Blockchain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBK#NASDAQ">ARBK</a>) shares decreased by 18.5% to $0.3 during Wednesday's pre-market session. The company's market cap stands at $23.4 million. </li>
<li>ClearOne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRO#NASDAQ">CLRO</a>) shares declined by 16.99% to $8.7. The company's market cap stands at $18.1 million. </li>
<li>Argo Blockchain plc - 8.75% Senior Notes due 2026 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARBKL#NASDAQ">ARBKL</a>) stock declined by 15.17% to $2.65. </li>
<li>Youxin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YAAS#NASDAQ">YAAS</a>) shares declined by 13.67% to $0.43. The company's market cap stands at $16.7 million. </li>
<li>Thumzup Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZUP#NASDAQ">TZUP</a>) shares fell 7.81% to $6.5. The market value of their outstanding shares is at $67.0 million. </li>
<li>BTCS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCS#NASDAQ">BTCS</a>) stock decreased by 7.73% to $2.15. The market value of their outstanding shares is at $49.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARBK

Argo Blockchain plc - 8.75% Senior Notes due 2026

ARBKL

BMNR

BTCS

BTOG

CLRO

GRYP

TZUP

VRNT

YAAS

12 Information Technology Stocks Moving In Wednesday's Pre-Market Session

Dividends

NTRB

Nutriband Board Approves 25% Preferred Stock Dividend; Shareholders Of Record On Jul. 25 Will Receive One Preferred Share For Every Four Common Shares Held

Board-Approved Allocation Reflects Long-Term Conviction in Bitcoin as a Strategic Reserve Asset and Foundation for Innovation Across Treasury and Product Strategy
Strategic Alignment Across Core Businesses of Wealth, Payments and Lending
Company Adopts Bitcoin as Corporate Hurdle Rate
Mogo Inc. ("Mogo" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>, TSX:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#TSX">MOGO</a>), a leading Canadian digital wealth and lending platform, today announced that its Board of Directors has authorized the allocation of up to $50 million to Bitcoin as part of the Company's long-term capital preservation and product innovation strategy. The move marks a significant step in Mogo's strategic alignment with Bitcoin, integrating it across treasury policy and its core operating platform.

TSX:MOGO

Mogo Board Authorizes Allocation Of Up To $50M To Bitcoin As Part Of Long-Term Capital Preservation And Product Innovation Strategy

Sunshine Biopharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched NIOPEG&#xAE;, the Company's first Biosimilar drug on the market.
NIOPEG&#xAE; is a Biosimilar comparable to the reference biologic drug NEULASTA&#xAE; (Pegfilgrastim). Like NEULASTA&#xAE;, NIOPEG&#xAE; is a long-acting, pegylated form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving chemotherapy. NIOPEG&#xAE; is available in a prefilled syringe of 6mg/0.6mL.
As of 2024, the global market size for NEULASTA&#xAE; and its biosimilars was estimated at $4.5 billion, with projections suggesting it could reach $9.2 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.5% (Verified Market Reports). The growth is largely driven by rising global cancer incidence and chemotherapy use.
The Canadian market for NEULASTA&#xAE; and its Biosimilars is smaller but still significant due to high biologics spending. Biologic drug sales in Canada reached $10 billion in 2020, accounting for about one-third of total pharmaceutical spending (<a href="https://pr.report/bzpa">www.canada.ca</a>). NEULASTA&#xAE; is one of the key biologics used in oncology, and its biosimilars have been gaining traction, especially after provincial switching policies were introduced to encourage cost savings.
Although Canada represents a smaller slice of the global market, its per capita biologics spending ranks among the highest in the OECD (Organisation for Economic Co-operation and Development), making it a valuable market for both branded and biosimilar products.
"The launch of NIOPEG&#xAE; as a biosimilar to NEULASTA&#xAE; represents a strategic milestone in our growth trajectory," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. By entering the high value-added biologics market with a cost-effective and clinically equivalent alternative, we are strengthening our portfolio, expanding our addressable market, and creating new revenue streams. This reinforces our commitment to delivering sustainable value to patients, the healthcare system, and our shareholders alike."

Sunshine Biopharma Announces That Its Wholly Owned Canadian Subsidiary, Nora Pharma, Has Launched Niopeg, The Company's First Biosimilar Drug

Earnings

Press Releases

Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update

Replimune Announces Inducement Grants Under Nasdaq  Listing Rule 5635(c)(4)

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

Replimune Announces Dates for Fiscal Fourth Quarter and Year End 2025 Financial Results and Upcoming Investor Day

Replimune Reports Fiscal Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

Replimune to Present at the 2025 Jefferies Global Healthcare Conference

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Comments

Replimune Group

Replimune Group (REPL) Opzioni

Replimune Group (NASDAQ:REPL) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO